Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Amgen naming Billy Kelleher .
Filed returns
7
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Amgen | EU Affairs | Correspondence on the proposed EU Biotech Act, including Amgen's proposed amendments (Legislation) | 3 | On lobbying.ie |
| Jan–Apr 2026 | Amgen | Health | Engagement with MEP Kelleher on EU legislations (Legislation) | 1 | On lobbying.ie |
| May–Aug 2025 | Amgen | Health | Requested a meeting with MEP Kelleher to introduce Amgen and discuss EU General Pharma Legislation, Critical Medicines Act, and the upcoming Biotech Act (Legislation) | 1 | On lobbying.ie |
| Jan–Apr 2025 | Amgen | Health | Email requesting a meeting with MEP Billy Kelleher to discuss EU legislation such as the Critical Medicines Act and upcoming Biotech Act (Legislation) | 1 | On lobbying.ie |
| Sep–Dec 2024 | Amgen | Health | Requested meetings to discuss need to prioritize EU health policy and enhance EU competitiveness in biotech and life sciences in Ireland (Legislation) | 5 | On lobbying.ie |
| Sep–Dec 2024 | Amgen | Health | Discussed EU competitiveness for biopharmaceutical industry investments at ALDE 2024 party conference roundtable; discussed Biotech Act, EU Pharma Legislation, and Draghi Report. (Legislation) | 1 | On lobbying.ie |
| Sep–Dec 2024 | Amgen | Health | Highlight importance of EU Biotech Act and finalization/implementation of EU Pharma Legislation, European Health Data Space, In Vitro Diagnostic Regulation and Clinical Trials Act as part of EU competitiveness. (Legislation) | 3 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 6 | 85.7% | |
| EU Affairs | 1 | 14.3% |